Stocks were higher Tuesday afternoon as investors digested earnings reports from several retailers and awaited results from ...

Shares of General Motors and Ford fall after President-elect Donald Trump announces his tariff plans, while Amgen tumbles as ...

Amgen (AMGN) is down more than -9% to lead losers in the S&P 500, the Dow Jones Industrials, and Nasdaq 100 after reporting that patients in an experimental trial lost about 20% of their body weight ...

The Dow Jones is treading choppy waters near 44,700 on Tuesday, finding an intraday floor near 44,400 before settling back into the day’s opening bids. The major equity index briefly set another ...

The thyroid medication levothyroxine may be associated with bone loss, according to a study that will be presented at the ...

Amgen reported 20% weight loss in its MariTide Phase II study results, but a 10% drop in share price suggests investors had ...

Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose an average of up to 20 percent of th ...

MariTide was administered monthly or less frequently, which could provide an edge over the popular weekly injections ...

MariTide’s Phase 2 press release “underwhelms” with 20% weight loss from Cohort A and 17% weight loss from Cohort B at 52-weeks, with it being unclear if these are placebo adjusted. MariTide’s weight ...

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...